Skip to main content
Category

Uncategorized

Cadence

By Uncategorized

 

Intracranial medical device

Founder: Mark Luciano

BHI Lead Contact: Albine Martin

Source: John Hopkins University

 

 

 

 

Artgen logo 04-e1455902609177

Artgen Inc.

By Uncategorized

 

Artgen logo 04-e1455902609177

Artgen, Inc. is a biotechnology company developing breakthrough treatments for vascular diseases. The company has a pipeline of preclinical therapeutic candidates with the first product (Art101) developed for treatment of Peripheral Arterial Disease (PAD).

Founders: Maxim Tvishor, Irena Tsyrlova

BHI Lead Contact: Albine Martin

Investment: Maryland Industral Partnerships (MIPS), Human Stem Cells Institute (Seed Investment)

*BHI Cofounded Company

 

 

 

 

bhi-board

BHI Appoints New Board Members From Roche, State Of Maryland

By Uncategorized

Juan Carlos Lopez of Roche and Mike Gill, Secretary for Maryland’s Department of Business and Economic Development, Join BHI Board

bhi-board

BioHealth Innovation, Inc. (BHI) announced today that its Board of Directors has unanimously voted and approved the appointments of Board Member Juan Carlos Lopez, Ph.D., Head of the Academic Relations and Collaborations (ARC) Group at Roche Pharma Research and Early Development (pRED), and Ex-Officio Board Member Mike Gill, Secretary, Department of Business and Economic Development (DBED), State of Maryland.

“We are pleased to have two powerhouse individuals join our dynamic board,” said Richard Bendis, BHI President and CEO. “We also want to thank Roche’s Dr. Judith Dunn for her commitment and service to our board during her tenure, which has now ended. We are grateful for her leadership and contributions during her time with us.”

Dr. Lopez leads the Roche pRED’s team in conducting outreach to academic and non-profit biomedical research and healthcare organizations for purposes of enhancing and complementing their internal R&D efforts. He began his career with the Nature Publishing Group in 2000, coming on board as an Associate Editor to launch Nature Reviews Neuroscience. In less than a year, he advanced to Chief Editor and led the publication to become the top monthly reviews journal in the neuroscience field, a position it retains to this day. In 2004, he was named Chief Editor at Nature Medicine, which is ranked by the Institute of Scientific Investigation as the world’s top journal in experimental and research medicine.

Read More

BioHealth Innovation’s Relevant Health Accelerator Recognized As One Of The Nation’s Leading Startup Accelerators By The U.S. Small Business Administration

By Uncategorized

Financial Award from SBA’s Accelerator Competition Supports Relevant Health’s Mission to Bring the Best Health Tech Products and Services to Market

ROCKVILLE, Md., Aug. 5, 2015 /PRNewswire/ — BioHealth Innovation’s Relevant Health, a recently launched health technology startup accelerator focused on bringing products to market, participated in the U.S. Small Business Administration’s (SBA) Second Annual Growth Accelerator Fund Competition. Relevant Health was among 80 winners from a pool of 400 applicants from across the country, including all 50 states, the District of Columbia and territories. Relevant Health was the only accelerator in Maryland to be recognized with this honor.

The total prize amount for all of the winning accelerators was $4.4 million, and the announcement came yesterday at 4:00 p.m. EDT when President Barack Obama formally named the winners during an event at the White House. The President discussed the future of innovation and entrepreneurship as demonstrated by individuals and businesses within the United States who participated in the White House Demo Day. SBA Administrator Maria Contreras-Sweet played a similar role in ceremonies in Los Angeles as part of the same program.

Each of the winning accelerators will be given $50,000 to aid in continuing to invest in the innovative startups and entrepreneurs who participate in the programs. In exchange for the recognition and funding that was awarded to them, the accelerators will be required to provide quarterly reports documenting metrics around the use of these funds, including job creation, additional funding generated, outside sponsorships and the status of startup launches.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.